Evidence map›Paper›PMID 24013185›Full record

ReviewNature reviews. Immunology2013

Tracking immune cells in vivo using magnetic resonance imaging.

Eric T Ahrens, Jeff W M Bulte

Abstract readReview
In one paragraph

Review in Nature reviews. Immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers.

0numbers the graph read from it
0cells of the map it votes in
246citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

246 citing papers in PubMed.

  1. PERFECTA Loaded Lipid Cubosomes forChemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  2. Review
  3. Review
  4. Endothelial Continuum and Capillary Specialization in Pulmonary Vascular Development.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Imaging the fate of CAR-T cellsFrontiers in immunology · 2026
    Review
  12. Review
  13. Preclinical Applications of Magnetic Resonance Imaging in Oncology.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Receptor-Mediated SPION Labeling of CD4Nanomaterials (Basel, Switzerland) · 2025
    Article
  20. Article

186 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Eric T AhrensDepartment of Radiology, University of California at San Diego, San Diego, California 92093-0695, USA.
Jeff W M Bulte

Funding

ValidationU54CA151838 · NCI · JOHNS HOPKINS UNIVERSITY · PI WANG, TZA-HUEI JEFF · 2010 to 2014
$11.9M
CLINICAL TRANSLATION OF 19F MRI TO VISUALIZE CANCER IMMUNOTHERAPEUTIC CELLSR01CA134633 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AHRENS, ERIC T., COHEN, EZRA · 2009 to 2021
$4.4M
MR Tracking of Magnetically Labeled Stem Cells in CNSR01NS045062 · NINDS · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2003 to 2013
$4.4M
Intracellular oxygen sensing using 19F MRIR01EB017271 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI AHRENS, ERIC T. · 2013 to 2016
$1.3M
Developing MPI for Non-Invasive and Quantitative Imaging of Stem CellsR01DA026299 · NIDA · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2008 to 2011
$1.3M
MR-Guided Delivery and Monitoring of Magnetocapsules Immunoprotecting Islet CellsR01EB007825 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI BULTE, JEFF W. · 2007 to 2008
$992k
Combined Optical/Micro-CT ScannerS10OD010744 · OD · HUGO W. MOSER RES INST KENNEDY KRIEGER · PI BULTE, JEFF W. · 2012 to 2012
$599k
NCI NIH HHS R01 CA134633NCI NIH HHS R01‑CA134633NCI NIH HHS U54 CA151838NCI NIH HHS U54‑CA151838NIBIB NIH HHS P41‑EB0019772NIBIB NIH HHS R01 EB007825NIBIB NIH HHS R01‑EB007825NIBIB NIH HHS R01 EB017271NIDA NIH HHS R01 DA026299NIDA NIH HHS R01‑DA026299NIH HHS S10 OD010744NINDS NIH HHS R01 NS045062NINDS NIH HHS R01‑NS045062
6 · The paper itself

Abstract

The increasing complexity of in vivo imaging technologies, coupled with the development of cell therapies, has fuelled a revolution in immune cell tracking in vivo. Powerful magnetic resonance imaging (MRI) methods are now being developed that use iron oxide- and ¹⁹F-based probes. These MRI technologies can be used for image-guided immune cell delivery and for the visualization of immune cell homing and engraftment, inflammation, cell physiology and gene expression. MRI-based cell tracking is now also being applied to evaluate therapeutics that modulate endogenous immune cell recruitment and to monitor emerging cellular immunotherapies. These recent uses show that MRI has the potential to be developed in many applications to follow the fate of immune cells in vivo.

Indexed as

AnimalsCell MovementCell TrackingContrast MediaFerric CompoundsFluorineFluorocarbonsHumansImage Interpretation, Computer-AssistedImmunotherapyIsotopesMagnetic Resonance ImagingMagneticsStaining and LabelingContrast MediaFerric Compoundsferric oxideFluorineFluorocarbonsIsotopes

Identifiers

PMID24013185
PMCPMC3886235

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.